» Articles » PMID: 35309855

A Conceptual Framework for Assessing the Public Health Effects from Snus and Novel Non-combustible Nicotine Products

Overview
Specialty Psychiatry
Date 2022 Mar 21
PMID 35309855
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The tobacco industry plans to base their future earnings on the production of non-combustible nicotine products. These might replace or come in addition to the more harmful cigarettes that historically have dominated the nicotine market in the Nordic countries. The authorities in each country must decide whether the products should have market access and, in that case, how strictly they should be regulated. Our aim is to present a framework that can assist the health authorities to make a regulation where benefits will outweigh the harms.

Method: In a public health perspective, health gains from substitution must be weighed against the health loss from additional use. The main elements of the weighing will be based on the information about the absolute risk of the products, their relative risk compared to conventional cigarettes and how the users are composed according to smoking status. We apply the framework on snus as used in Norway - a product with an established usage pattern and epidemiologically assessed health risks.

Results: The framework consists of (i) a comprehensive set of specific user patterns that may result in health deterioration and user patterns that may result in health benefits, (ii) an estimation of the number of people with health-augmenting and health-impairing user patterns, respectively, and (iii) an estimation of the degree of health deterioration or health benefit that will affect the persons with the different user patterns.

Conclusion: The net effect on public health will appear as an overall result of the number of people with positive and negative user patterns, respectively, in combination with the magnitude of the change in health status these people will experience. The use of an explicit framework highlights how a political decision may affect nicotine use and health-related outcomes. The framework breaks open a large and complex question into smaller pieces and requires the authorities to expose and explain the kind of evidence and reasoning behind regulations of novel nicotine products.

Citing Articles

Challenges in legitimizing further measures against smoking in jurisdictions with robust infrastructure for tobacco control: how far can the authorities allow themselves to go?.

Lund K, Saebo G Harm Reduct J. 2024; 21(1):33.

PMID: 38321438 PMC: 10848560. DOI: 10.1186/s12954-024-00951-w.


Future nicotine use preferences of current cigarette smokers: Findings from the 2020 International Tobacco Control Four Country Smoking and Vaping Survey.

Li L, Borland R, Le Grande M, Gartner C Drug Alcohol Rev. 2023; 43(2):359-370.

PMID: 38113310 PMC: 10922120. DOI: 10.1111/dar.13791.


How do Smokers in a Snus-Prevalent Society Consider E-cigarettes, Snus, and Nicotine Replacement Therapy Products as Relevant Replacements for Cigarettes in the Event They Should Stop Smoking?.

Vedoy T, Lund K Nicotine Tob Res. 2023; 25(11):1753-1761.

PMID: 37410922 PMC: 10475606. DOI: 10.1093/ntr/ntad113.


Oral nicotine pouches with an aftertaste? Part 1: screening and initial toxicological assessment of flavorings and other ingredients.

Mallock-Ohnesorg N, Rinaldi S, Malke S, Dreiack N, Pieper E, Laux P Arch Toxicol. 2023; 97(9):2357-2369.

PMID: 37389646 PMC: 10404176. DOI: 10.1007/s00204-023-03538-9.


A Decision-Theoretic Public Health Framework for Heated Tobacco and Nicotine Vaping Products.

Levy D, Cadham C, Li Y, Yuan Z, Liber A, Oh H Int J Environ Res Public Health. 2022; 19(20).

PMID: 36294011 PMC: 9602493. DOI: 10.3390/ijerph192013431.


References
1.
Lund I, Lund K . How has the availability of snus influenced cigarette smoking in Norway?. Int J Environ Res Public Health. 2014; 11(11):11705-17. PMC: 4245639. DOI: 10.3390/ijerph111111705. View

2.
Weitkunat R, Lee P, Baker G, Sponsiello-Wang Z, Gonzalez-Zuloeta Ladd A, Ludicke F . A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product. Regul Toxicol Pharmacol. 2015; 72(1):87-93. DOI: 10.1016/j.yrtph.2015.03.011. View

3.
Gottlieb S, Zeller M . A Nicotine-Focused Framework for Public Health. N Engl J Med. 2017; 377(12):1111-1114. DOI: 10.1056/NEJMp1707409. View

4.
Phillips C . Gateway Effects: Why the Cited Evidence Does Not Support Their Existence for Low-Risk Tobacco Products (and What Evidence Would). Int J Environ Res Public Health. 2015; 12(5):5439-64. PMC: 4454978. DOI: 10.3390/ijerph120505439. View

5.
Furberg H, Bulik C, Lerman C, Lichtenstein P, Pedersen N, Sullivan P . Is Swedish snus associated with smoking initiation or smoking cessation?. Tob Control. 2005; 14(6):422-4. PMC: 1748128. DOI: 10.1136/tc.2005.012476. View